

Does cannabidiol have antiseizure activity independent of antiepileptic drugs? An appraisal of the evidence from randomized controlled trials

Epilepsia

61, 1082-1089

DOI: [10.1111/epi.16542](https://doi.org/10.1111/epi.16542)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Biochemical aspects and therapeutic mechanisms of cannabidiol in epilepsy. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 1214-1228.	2.9	10
2	Cannabidiol efficacy and clobazam coadministration: Where do we stand now?. <i>Epilepsia</i> , 2020, 61, 1795-1796.	2.6	3
3	Cannabidiol antiseizure activity and its interactions with clobazam: "œltâ™s d'œj' vu all over again" Yogi Berra. <i>Epilepsia</i> , 2020, 61, 1791-1792.	2.6	0
4	Therapeutic advances in Dravet syndrome: a targeted literature review. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1065-1079.	1.4	44
5	Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 531-540.	1.0	33
6	Response: Cannabidiol antiseizure activity and its interactions with clobazam: "œltâ™s d'œj' vu all over again" Yogi Berra. <i>Epilepsia</i> , 2020, 61, 1793-1794.	2.6	0
7	Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 154-163.	1.0	20
8	Anticonvulsant Agents: Pharmacology and Biochemistry. , 2021, , 1-27.		0
9	Cannabidiol in the Treatment of Epilepsy. <i>Clinical Drug Investigation</i> , 2021, 41, 211-220.	1.1	23
10	From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?. <i>Frontiers in Psychiatry</i> , 2021, 12, 638032.	1.3	7
11	Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. <i>Neuropharmacology</i> , 2021, 185, 108442.	2.0	43
12	Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program. <i>Frontiers in Pharmacology</i> , 2021, 12, 637801.	1.6	21
13	Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4294.	1.8	30
14	Cannabinoids in Neurology - Position paper from Scientific Departments from Brazilian Academy of Neurology. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 354-369.	0.3	7
15	The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. <i>CNS Drugs</i> , 2021, 35, 935-963.	2.7	108
16	The CB2 Receptor as a Novel Therapeutic Target for Epilepsy Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8961.	1.8	13
17	Pharmacokinetic Drug-Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9582.	1.8	26
18	The pharmacological treatment of epilepsy: recent advances and future perspectives. <i>Acta Epileptologica</i> , 2021, 3, .	0.4	30

#	ARTICLE	IF	CITATIONS
19	Impact of smoking cannabidiol (CBD)-rich marijuana on driving ability. <i>Forensic Sciences Research</i> , 2021, 6, 195-207.	0.9	7
20	Selection of antiseizure medications for first add-on use: A consensus paper. <i>Epilepsy and Behavior</i> , 2021, 122, 108087.	0.9	6
21	Anticonvulsant Agents: Pharmacology and Biochemistry. , 2021, , 1-27.		0
22	Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies. <i>CNS Drugs</i> , 2021, 35, 61-83.	2.7	39
23	Channelopathy of Dravet Syndrome and Potential Neuroprotective Effects of Cannabidiol. <i>Journal of Central Nervous System Disease</i> , 2021, 13, 117957352110480.	0.7	4
24	New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 975.	1.8	32
25	A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development. <i>Epilepsy and Behavior</i> , 2022, 128, 108577.	0.9	8
26	A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. <i>CNS Drugs</i> , 2022, 36, 217-237.	2.7	38
27	Cannabis for Rheumatic Disease Pain: a Review of Current Literature. <i>Current Rheumatology Reports</i> , 2022, 24, 119-131.	2.1	6
28	Reply to comments on "A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development" <i>Epilepsy and Behavior</i> , 2022, 131, 108704.	0.9	0
29	Current Principles in the Management of Drug-Resistant Epilepsy. <i>CNS Drugs</i> , 2022, 36, 555-568.	2.7	6
30	Cannabidiol treatment for seizures in tuberous sclerosis complex. <i>Epilepsy and Behavior</i> , 2022, 132, 108761.	0.9	1
31	Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	14
32	Current and future pharmacotherapy options for drug-resistant epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 2023-2034.	0.9	8
33	Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. <i>Experimental Neurology</i> , 2023, 359, 114238.	2.0	11
34	Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. <i>Experimental Neurology</i> , 2023, 359, 114237.	2.0	24
35	Cannabidiol drug interaction considerations for prescribers and pharmacists. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1383-1397.	1.3	7
36	Anti-convulsant Agents: Pharmacology and Biochemistry. , 2022, , 3413-3439.		0

#	ARTICLE	IF	CITATIONS
37	Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam. <i>Experimental Neurology</i> , 2023, 360, 114286.	2.0	3
38	The cenobamate-clobazam interaction- evidence of synergy in addition to pharmacokinetic interaction. <i>Epilepsy and Behavior</i> , 2023, 142, 109156.	0.9	3
39	Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. <i>Epilepsy and Behavior</i> , 2023, 141, 109159.	0.9	10